Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label tolebrutinib extension study in multiple sclerosis
NL-OMON59289Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tolebrutinib in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) (3 arms), sponsored by Sanofi. Primary endpoints: Number of participants with adverse events and Number of participants with potentially clinically significant abnormalities. Started Jun 2024; status: recruiting.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON59289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59289.